ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) — Recruiting • Phase I • Oncology • NCT07602777.
- Treatment being tested: Risvutatug Rezetecan (Ris-Rez), a novel therapeutic agent being evaluated for efficacy and safety in patients with advanced sarcomas, with assessment of tolerability and pharmacokinetic profile.
- Patient eligibility overview: The trial targets patients with advanced sarcomas; specific eligibility criteria including disease stage, prior treatment history, and performance status would determine participant suitability.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like…
Eligibility Snapshot
- : - Participants are eligible to be included in the study only if all of the following criteria apply * Participants must be ≥ 12 years of age. * Has histologically confirmed unresectable advanced or metastatic R/R OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has progressed to at least one prior line of systemic therapy. * Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging * Has an ECOG performance status of 0 or 1, or Lansky PS/Karnofsky PS ≥ 70% for adolescent participants, with no deterioration in the 2 weeks prior to first dose/randomization. * Has adequate organ function. * All participants, or their legal guardians, must provide signed informed consent and agree to follow the study protocol before starting any study activities
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.